bit.bio secures $50 million Series C funding
CAMBRIDGE, England, Jan. 9, 2026 - bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding round led by M&G Investments. This injection of patient capital from a major UK investor represents a significant endorsement of our mission to transform the future of drug development and innovation within the United Kingdom.
This capital infusion allows us to move toward several key strategic milestones, including accelerating the development and delivery of our core product pipeline while scaling our operational footprint to meet global demand. We are expanding into the multi-billion dollar toxicology market and generating the high-fidelity datasets necessary to train advanced AI models for drug discovery.
Central to this effort is our ioCells™ technology, which facilitates a global shift toward New Approach Methodologies (NAMs), in particular, advanced cell-based models that improve the predictiveness of new medicines while reducing industry reliance on animal testing.
Alongside this funding, we are pleased to welcome Lord David Prior to our leadership team as an independent director and Board Chair. Lord Prior’s twenty-year tenure in UK Life Sciences and health policy will be vital as we navigate our growth from a private entity toward public markets.
Przemek Obloj, CEO of bit.bio, commented:
Cornel Chiriac, Investment Director of Crossover, M&G Investments, said:"By providing reliable human cells for research and safety testing, we’re helping to accelerate drug development and build a world class life sciences business in the UK. Our technology reduces reliance on animal testing while improving the relevance and accuracy of pre-clinical research. With fresh backing from M&G and our wider investor base, we can accelerate development, from in silico model training through our most established in vitro discovery models and towards safety testing."